Renal tubular acidosis

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Daily non-volatile acid is buffered and excreted mainly as ammonium and titratable acid while filtered bicarbonate is reclaimed. Proximal tubules reabsorb most bicarbonate; distal nephron proton secretion and ammonium handling generate the final acid excretion. A defect at either site lowers serum bicarbonate and raises chloride to preserve electroneutrality. The serum anion gap therefore remains normal unless another process coexists, and albumin must be considered because hypoalbuminaemia lowers the expected gap.

Type 1 disease may be inherited or acquired through autoimmune disease, especially Sjogren syndrome, obstructive or interstitial disorders, or medicines such as amphotericin. Persistent alkaline urine, calcium-phosphate supersaturation and low citrate promote nephrocalcinosis. Type 2 may be isolated but more often sits within Fanconi syndrome due to drugs, monoclonal light chains or inherited proximal disorders. Type 4 results from hyporeninaemic hypoaldosteronism or collecting-duct resistance; diabetes, CKD and ACE inhibitors, ARBs, mineralocorticoid antagonists, trimethoprim and potassium-sparing diuretics can contribute.

Classification should guide treatment rather than become a label derived from one urine pH. Paired blood and fresh urine studies obtained before large alkali doses are most informative, although urgent electrolyte treatment must never be delayed. The urine anion gap is sometimes used as a surrogate for ammonium excretion, but it has limitations and nephrology advice is appropriate when mixed disease, reduced GFR or unusual urinary anions make it unreliable.

Key points

RTA is a renal acidification defect that usually causes a normal-anion-gap, hyperchloraemic metabolic acidosis out of proportion to any reduction in glomerular filtration.
First confirm genuine metabolic acidosis and exclude gastrointestinal bicarbonate loss, chloride-rich fluid administration, ketoacidosis masked by mixed disorders, toxins and advanced CKD.
Distal type 1 RTA impairs urinary hydrogen secretion, often leaves urine inappropriately alkaline during systemic acidosis, and is associated with hypokalaemia, hypocitraturia, stones and nephrocalcinosis.
Proximal type 2 RTA reflects bicarbonate wasting; urine becomes acidic after plasma bicarbonate falls below the reduced reabsorptive threshold, and generalised proximal loss indicates Fanconi syndrome.
Type 4 RTA is characterised by hyperkalaemia from deficient or ineffective aldosterone action, commonly with diabetic kidney disease, interstitial disease or medicines affecting the renin-aldosterone-distal sodium pathway.
Urine pH is only interpretable in a fresh sample during confirmed acidosis; urea-splitting infection, diet, low distal sodium delivery and sample delay can mislead.
Treatment combines cause removal with potassium management and individually titrated bicarbonate or citrate; proximal RTA often needs much more alkali than distal disease.
Potassium citrate can be useful in hypokalaemic stone-forming distal RTA but is dangerous in hyperkalaemia or significant renal impairment and belongs under specialist monitoring.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Distal acidification failure

Autoimmune disease, inherited transport defects, medicines, obstruction and interstitial damage can impair distal hydrogen secretion, often with hypokalaemia and stone risk.

Proximal bicarbonate wasting

Selective transport defects or generalised Fanconi syndrome reduce proximal bicarbonate reclamation, often alongside medicine, toxin, monoclonal or inherited disease.

Hypoaldosterone or resistant state

Diabetic kidney disease, chronic interstitial disease and medicines affecting renin, aldosterone or distal sodium delivery can produce hyperkalaemic type 4 RTA.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Reduced net acid excretion
Tubular acid-handling failure retains hydrogen relative to chloride, producing a hyperchloraemic normal-anion-gap metabolic acidosis disproportionate to filtration loss.
2
Distal hydrogen-secretory defect
Failure to acidify collecting-duct urine reduces ammonium trapping and citrate, promoting alkaline urine, hypokalaemia, stones and nephrocalcinosis.
3
Proximal bicarbonate loss
A lowered reabsorptive threshold causes bicarbonaturia until plasma bicarbonate falls sufficiently, after which distal segments can still acidify urine.
4
Aldosterone-pathway failure
Reduced aldosterone effect or distal sodium delivery impairs potassium and hydrogen secretion, coupling hyperkalaemia to type 4 acidosis.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Distal stone phenotype

Recurrent calcium stones or nephrocalcinosis with hypokalaemic hyperchloraemic acidosis and inappropriately alkaline urine suggests distal acidification failure.

Proximal wasting

Acidosis accompanied by normoglycaemic glycosuria, phosphate or urate loss, aminoaciduria and tubular proteinuria is Fanconi syndrome rather than isolated distal disease.

Hyperkalaemic patternRed flag

Mild metabolic acidosis with persistent hyperkalaemia in diabetic or interstitial CKD, especially during RAAS or ENaC-blocking therapy, suggests type 4 physiology.

Muscle emergencyRed flag

Palpitations, syncope, ascending weakness or paralysis can result from severe potassium disturbance and require immediate ECG and biochemical assessment.

Autoimmune clue

Sicca symptoms, arthralgia, purpura or another systemic phenotype with distal RTA should prompt targeted autoimmune investigation rather than acid replacement alone.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Venous or arterial blood gasFirst step
Why
Confirm metabolic acidosis and assess severity and respiratory compensation.
Interpretation and limitations
Low bicarbonate with acidemia supports the diagnosis; an unexpected carbon dioxide response signals a concurrent respiratory disorder.
02
Serum electrolytes and anion gap
Why
Distinguish hyperchloraemic acidosis and define the potassium phenotype.
Interpretation and limitations
Calculate sodium minus chloride and bicarbonate and interpret against albumin; a raised gap or delta discrepancy indicates a mixed metabolic process.
03
Fresh urine pH and culture
Why
Assess distal acidification while excluding an alkaline infected sample.
Interpretation and limitations
Urine pH above about 5.5 during established systemic acidosis supports distal RTA but is not diagnostic without context; urease-positive infection can raise pH.
04
Urine electrolytes
Why
Estimate renal ammonium response and explore renal potassium loss.
Interpretation and limitations
A positive urine anion gap may suggest low ammonium excretion, but reduced GFR, ketoanions, drugs and low sodium delivery limit the inference.
05
Calcium imaging and urine risk
Why
Find nephrocalcinosis and quantify stone-promoting abnormalities in suspected distal RTA.
Interpretation and limitations
Ultrasound may show calcification; specialist 24-hour urine calcium and citrate testing helps tailor alkali and stone prevention.
06
Aetiology investigations
Why
Identify autoimmune, monoclonal, drug-related, obstructive or inherited causes.
Interpretation and limitations
Choose glucose, phosphate, urate, ACR and PCR, immunoglobulins and free light chains, autoimmune tests, imaging or genetics from the RTA subtype and age.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Gastrointestinal bicarbonate loss

Diarrhoea and enteric losses cause similar normal-gap acidosis but usually stimulate appropriate renal ammonium excretion rather than intrinsic acidification failure.

Chloride-rich fluid administration

A recent large chloride load lowers bicarbonate through strong-ion effects without a persistent tubular transport disorder.

Advanced chronic kidney disease

Global nephron loss reduces ammonium and acid excretion, eventually adding retained unmeasured acids; the acidosis then tracks filtration rather than a selective tubular defect.

Mixed or high-anion-gap acidosis

Ketoacidosis, lactic acidosis and toxins may be obscured by concurrent chloride disturbance, so the anion gap and clinical generator still require review.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01ConfirmVerify renal acidosisFirst stepRoutine chemistry shows a low bicarbonate concentration.

1Repeat or obtain a blood gas when artefact or respiratory alkalosis is possible, while checking chloride, potassium, renal function, glucose, lactate and ketones.
2Calculate and albumin-adjust the anion gap, then seek diarrhoea, urinary diversion, saline administration, toxins and reduced-GFR explanations.
3Collect fresh urine pH, culture and electrolytes before alkali when clinically safe, and involve nephrology if the physiology remains mixed or uncertain.

02ClassifyUse potassium and urine phenotypeA persistent normal-gap metabolic acidosis remains unexplained.

1Recognise distal RTA from failed urine acidification, hypokalaemia and stone or nephrocalcinosis features, then screen for autoimmune and drug causes.
2Look for generalised proximal solute loss when proximal RTA is possible and assess for medicines, monoclonal light chains and inherited Fanconi disorders.
3For hyperkalaemia, review diabetes, renal function, renin-aldosterone pathway medicines, trimethoprim, obstruction and adrenal disease before assigning type 4 RTA.

03CorrectReplace potassium and alkaliRTA is confirmed and immediate resuscitation is not required.

1In hypokalaemic disease, correct dangerous potassium depletion first or alongside alkali because bicarbonate delivery can drive potassium lower.
2Select sodium bicarbonate or a citrate salt with renal expertise, accounting for blood pressure, oedema, stone risk, sodium load and kidney function.
3Titrate to symptoms, serum bicarbonate, potassium and urine stone parameters rather than copying a fixed dose across different RTA subtypes.

04RescueTreat hyperkalaemic RTA safelyType 4 physiology causes moderate or severe potassium elevation.

1Obtain an ECG and grade urgency; use the local UKKA-aligned emergency sequence for severe hyperkalaemia or ECG toxicity.
2Address acute kidney injury, obstruction, constipation, acidosis, dietary sources and culpable medicines while preserving prognostically valuable RAAS therapy when safely possible.
3Agree longer-term diuretic, bicarbonate, potassium-binder or rare mineralocorticoid strategies with renal specialists and monitor after every change.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Replaces alkali, raises serum bicarbonate and can reduce bone buffering, catabolism and hypocitraturic stone risk.

Sodium bicarbonate

For chronic renal tubular acidosis, initiate and titrate using the current BNF and specialist plan; the required dose varies substantially with subtype and ongoing bicarbonate loss.

Monitor sodium load, blood pressure, oedema, potassium and gastrointestinal tolerance. Large doses may be required in proximal RTA and can worsen hypokalaemia.

Provides both potassium and alkali in selected hypokalaemic distal RTA, particularly where hypocitraturia contributes to stones.

Potassium citrate with potassium bicarbonate

Use only through a renal or metabolic stone service, divided and titrated to potassium, bicarbonate and urine citrate using the live BNF product guidance.

Avoid or use extreme caution with hyperkalaemia, interacting potassium-raising drugs or impaired excretion; gastrointestinal injury and rapid potassium change are important risks.

May increase distal sodium delivery and potassium excretion in selected type 4 RTA, or support specialist management of high alkali requirements.

Loop or thiazide-type diuretic

Choose and dose from the local formulary only when volume status and renal function support use, with early electrolyte and creatinine review.

Can cause hypovolaemia, AKI, hyponatraemia, gout and excessive potassium loss. It is not a substitute for emergency hyperkalaemia treatment.

Enhances distal sodium reabsorption and potassium and hydrogen secretion when aldosterone deficiency is central to type 4 physiology.

Fludrocortisone

Reserve for selected proven mineralocorticoid-deficient states under specialist direction, using the lowest effective dose and explicit monitoring.

May cause hypertension, oedema, heart failure and hypokalaemia; it is usually unsuitable when sodium retention or cardiovascular disease is prominent.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Potassium-related arrhythmia

Distal and proximal disease may cause profound hypokalaemia, while type 4 disease causes hyperkalaemia; either extreme can impair cardiac conduction and muscle function.

Nephrolithiasis and nephrocalcinosis

Alkaline urine, low citrate and calcium mobilisation in distal RTA promote crystal formation, recurrent colic, infection and additional renal damage.

Bone demineralisation

Chronic buffering of retained acid consumes bone mineral and impairs mineralisation, producing osteomalacia, pain, weakness or rickets in children.

Progressive kidney impairment

Recurrent stones, nephrocalcinosis and the underlying tubulointerstitial disorder can reduce renal reserve, while falling filtration further worsens acidosis.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Repeat bicarbonate, chloride, potassium, creatinine and magnesium after starting or changing alkali, potassium or diuretic treatment.
Monitor blood pressure, weight and oedema where sodium bicarbonate or mineralocorticoid therapy increases sodium retention.
In distal RTA, follow stone events, renal imaging and specialist urine calcium and citrate measures to assess nephrocalcinosis risk.
For proximal disease, track phosphate, urate, glucose-associated urine loss, bone symptoms and other Fanconi markers rather than bicarbonate alone.
Reconcile ACE inhibitors, ARBs, mineralocorticoid antagonists, trimethoprim, NSAIDs and potassium products whenever type 4 RTA destabilises.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Urine pH changes proximally

In proximal RTA, urine may become appropriately acidic once plasma bicarbonate has fallen below the reduced reabsorptive threshold.

Albumin alters the gap

A seemingly normal anion gap in marked hypoalbuminaemia can conceal accumulated unmeasured anions and a mixed acidosis.

Citrate links treatment and stones

Correcting distal acidosis can increase urinary citrate, reducing one important driver of calcium stone formation.

Type four is not always adrenal failure

Diabetic hyporeninaemia, interstitial damage and collecting-duct medicines commonly produce aldosterone deficiency or resistance without primary Addison disease.

Low GFR complicates classification

Advanced CKD itself impairs ammonium excretion, so classic RTA tests become less specific as filtration declines.

11Common pitfallsFrequent interpretation and management errors.

01
Diagnosing distal RTA from one alkaline urine sample collected after a meal, during infection or after alkali therapy.
02
Failing to calculate the anion gap and missing ketoacidosis, lactate accumulation or a mixed metabolic disorder.
03
Giving bicarbonate before addressing severe hypokalaemia and precipitating further potassium decline.
04
Using potassium citrate in hyperkalaemic type 4 disease or significant renal impairment without specialist oversight.
05
Stopping all RAAS blockade reflexively for mild chronic hyperkalaemia without weighing cardiovascular and kidney benefit.
06
Treating numbers indefinitely without finding Sjogren syndrome, a monoclonal process, a medicine or urinary obstruction.